FDA issues Class II recall of thousands of blood‑pressure pills from Macleods Pharma USA

OBBM Network Editorial Staff

November 3, 2026

Fda Issues Class Ii Recall Of Thousands Of Blood Pressure Pills From Macleods Ph

The U.S. Food and Drug Administration is urging consumers across the country to check their medicine cabinets after a large‑scale recall of blood‑pressure medication. The agency announced that Macleods Pharma USA, a New Jersey manufacturer, is recalling specific lots of three common antihypertensive tablets: Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide.

Recall details and scope

The recall was first issued on October 7, 2026, and the FDA later assigned it a Class II rating on October 26, 2026. A Class II recall indicates that use of the affected medication could cause “temporary or medically reversible adverse health consequences.” The FDA’s enforcement report states that the pills did not dissolve as required during standard quality‑control testing, raising concerns about their effectiveness in controlling blood pressure.

According to the FDA’s website, the recall covers:

3,528 bottles containing 30 tablets each, identified as lot 12251163A.
216 bottles containing 90 tablets each, identified as lot 12251163B.

Both lots carry an expiration date of May 31, 2027.

How consumers can protect themselves

Patients who have been prescribed any of the three medications should locate the lot numbers on their bottle labels. If the lot numbers match those listed above, they should stop using the medication immediately and contact their pharmacy or health‑care provider for a replacement. The FDA advises returning the recalled bottles to the place of purchase for a full refund.

Pharmacies and health‑care providers have been notified of the recall and are instructed to remove the affected stock from shelves. The agency also recommends that physicians consider alternative antihypertensive therapies for patients currently taking the recalled products.

Recent related recalls

This recall follows earlier actions by the FDA involving blood‑pressure drugs. In June, Inventia Healthcare recalled certain lots of chlorthalidone tablets, and on September 3, 2026 the company initiated a separate recall of an additional lot, which the FDA also classified as Class II on September 17, 2026.

Why the recall matters

Hypertension remains a leading risk factor for heart disease and stroke in the United States. Ensuring that medications work as intended is critical for protecting public health. The FDA’s swift classification of this recall as Class II underscores the agency’s commitment to safeguarding the efficacy of essential medicines.

Patients who have concerns about their blood‑pressure treatment should consult their doctors promptly. Health‑care professionals can provide guidance on alternative medications, dosage adjustments, or additional monitoring to maintain safe blood‑pressure levels while the recall is processed.

What’s next

The FDA will continue to monitor the situation and may issue further updates if additional information becomes available. Consumers can stay informed by visiting the FDA’s official recall webpage or signing up for email alerts on medication safety.

Original reporting: KOAT Albuquerque — read the source article.